IgA肾病治疗研究进展及展望  

Research Progress and Prospects of IgA Nephropathy

作　　者：王冰心 李贞琼[2] WANG Bingxin;LI Zhenqiong(The First Clinical Medical School of Tongji Medical College,Wuhan 430030,China;不详)

机构地区：[1]同济医学院第一临床学院,湖北武汉430030 [2]华中科技大学同济医学院附属协和医院

出　　处：《中外医学研究》2023年第15期163-168,共6页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：IgA肾病是全球最常见的原发性肾小球疾病,其是一种缓慢进展的疾病,目前尚无特异性治疗方法,且糖皮质激素和免疫抑制剂的治疗作用一直存在争议。随着生物科学和医学技术进步,肠道黏膜免疫、补体系统、内皮素(ET)受体及B细胞活化因子(B cell activating factor,BAFF)/增殖诱导配体(a proliferation-inducing ligand,APRIL)系统等被证实在IgA肾病发生发展中发挥重要作用。这些新进展为推测发病机制提供了理论依据,也为研发新型药物提供了方向。本文主要对IgA肾病药物治疗现状及其存在的问题进行综述。IgA nephropathy is the most common primary glomerular disease in the world.It is a slow-progressing disease with no specific treatment at present,and the therapeutic effects of glucocorticoid and immunosuppressant have always been controversial.As biological science and medical technology advance,intestinal mucosal immunity,complement system,endothelin(ET)receptors,and B cell activating factor(BAFF)/a proliferation-inducing ligand(APRIL)system etc has been confirmed to play an important role in the occurrence and development of IgA nephropathy.These new developments provide a theoretical basis for predicting the pathogenesis and a direction for developing new drugs.This article mainly reviews the treatment status and existing problems of IgA nephropathy drug treatment.

关 键 词：IGA肾病 钠-葡萄糖共转运蛋白2 抑制剂 内皮素受体拮抗剂 补体抑制剂 

分 类 号：R692.3[医药卫生—泌尿科学]